Monitor upcoming safety reviews and data readouts from ABACUS-2 and KLARITY trials in H1 2027. The $5M equity raise provides near-term financial stability but dilutes existing shareholders.
Price Chart
Executive Summary
Kiora Pharmaceuticals reported a Q1 2026 net loss of $2.4M, wider than the $2.2M loss in Q1 2025, driven by higher R&D and G&A expenses. The company highlighted strong enrollment in its Phase 2 ABACUS-2 trial and a $5M equity raise post-quarter, extending its cash runway into late 2028. As a pre-revenue clinical-stage biotech, the filing is neutral as it reflects routine operational progress without material financial surprises.
Key Financial Metrics
Key Facts
- Q1 2026 net loss of $2.4M vs $2.2M in Q1 2025
- Cash and short-term investments of $13.9M at quarter end
- Raised $5.0M in gross proceeds from strategic equity financing post-quarter
- Cash runway extended into late 2028, beyond anticipated data readouts
- Enrollment in Phase 2 ABACUS-2 study of KIO-301 is close to 50% completed
- Publication of ABACUS-1 results in Nature Medicine in April 2026
Financial Impact
Net loss increased by $0.2M year-over-year; no revenue reported
Risk Factors
- Clinical trial failure or delays for KIO-301 or KIO-104
- Further dilution from additional equity financings
- No approved products or revenue stream
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001372514-26-000048 |
| Document: kprx-20260508.htm | 0001372514-26-000048 |
| Document: 0001372514-26-000048-index-headers.html | 0001372514-26-000048 |
| Document: 0001372514-26-000048-index.html | 0001372514-26-000048 |
| Document: 0001372514-26-000048.txt | 0001372514-26-000048 |
| 8-K Data (Synthetic) | 0001372514-26-000048 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
May 26, 2026 22w ago | EFFECT | — | awaiting T+20 | — | — |
May 8, 2026 24w ago | 8-K | — | awaiting T+20 | — | — |
Apr 7, 2026 29w ago | 8-K | — | awaiting T+20 | — | — |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers